AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration

07:52 EDT 29 Mar 2019 | Pharmafile

AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see the two companies put their heads together to develop and commercialise the latter’s cancer therapy trastuzumab deruxtecan.

According to a release form AZ, the partnership will seek to “accelerate and expand development of trastuzumab deruxtecan across breast and other cancers, with the potential to redefine standard of care.”

AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration

AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see the two companies put their heads together to develop and commercialise the latter’s cancer therapy trastuzumab deruxtecan.

More From BioPortfolio on "AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration"